India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published to IGC’s website, provides an overview of the company’s initiatives in life sciences. These include IGC’s focus on low-dose THC-based drug formulation and … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Files Updated Life Sciences Presentation”
India Globalization Capital (NYSE American: IGC) applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act, which was signed into law by President Biden on Friday Dec. 2, 2022. The legislation establishes a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development. “The … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Applauds Milestone Development for Medical Cannabis Industry”
India Globalization Capital (NYSE American: IGC) announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” According to the announcement, the company has commenced the phase 2 study at two U.S. sites and plans to … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Commences Trial Evaluating IGC-AD1 for the Treatment of Alzheimer’s-Related Symptoms”
India Globalization Capital (NYSE American: IGC) has announced that its Chief Executive Officer Ram Mukunda will be presenting at the RHK Disruptive Growth Conference in New York City. Mukunda is slated to present beginning at 11:20 a.m. ET on Monday, Dec. 5, and will also be available for one-on-one meetings on Monday, Dec. 5 and … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Present at RHK 2022 Disruptive Growth Conference”
India Globalization Capital (NYSE American: IGC) is reporting financial results for second quarter 2023, the period ending Sept. 30, 2022. Highlights of the report include the potential shown by IGC-AD1 and TGR-63, the company’s main investigational drug assets, to suppress or ameliorate a key protein in Alzheimer’s cell lines that are responsible for Aβ plaques, … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Numbers for Q2”
IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients The company’s other drug … Continue reading “India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’”
Included are drugs formulated to treat Alzheimer’s, Parkinson’s, eating disorders and seizures IGC already has seven provisional filings for phytocannabinoid-based combination therapies Company also has in its pipeline combination therapy drug candidates for the treatment of end points of Parkinson’s, as well as epilepsy in cats and dogs India Globalization Capital, Inc. (NYSE American: IGC) … Continue reading “India Globalization Capital, Inc. (NYSE: IGC) Anticipates Filing Patents for Portfolio of Drug Candidates in 2018-2019”
India Globalization Capital (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, has recently developed IGC-506 for the treatment of multiple types of eating disorders in humans, as well as animals in the veterinary market. The company expects to file a Patent Cooperation Treaty (“PCT”) application by February 28, … Continue reading “NetworkNewsBreaks – India Globalization Capital, Inc.’s (NYSE: IGC) Cannabis-based Eating Disorder Treatment Anticipated for PCT Filing in February”
Filing for IGC-506 anticipated to be completed in the U.S. in 2019, expanding the company’s patent portfolio; company is looking at pre-clinical trials for three of its combination drugs, possibly creating enhanced valuation IGC has pre-clinical trial scheduled in 2018 for IGC-AD1, a combination-therapy drug designed to treat Alzheimer’s IGC-506 is a combination therapy developed … Continue reading “India Globalization Capital, Inc. (NYSE: IGC) Targets February 2018 International Patent Filing for Eating Disorder Drug”
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced plans to leverage its existing team of technology and health care experts in order to develop methods of utilizing blockchain technology in areas such as product identification assurance (PIA). The importance of PIA … Continue reading “NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Looks to Blockchain Technology as Possible Solution for Issues Facing Cannabis Industry”
